“BUSINESS: Can One Business Unit Have Two Revenue Models?” October 8, 2024 The difference in Siiquent’s and Teomik’s business model reminded me a case study we read for my BUSGEN105 class, where we analyized two existing companies’… Continue Reading
BUSINESS: Can One Business Unit Have Two Revenue Models? October 8, 2024 This week’s reading describes the challenge of Peter Noll, chief of Scherr Diagnostic Divisions, in finding an optimized single revenue model for the merge… Continue Reading
Can One Business Unit Have Two Revenue Models? October 8, 2024 Business and Revenue Models Both businesses operate in the genetic tech market. While Isolde focuses on medical diagnostics, Emmanuel focuses more on research. Isolde… Continue Reading
Can One Business Unit Have Two Revenue Models? October 8, 2024 Isolde’s company is Siiquent, which sells everything that hospitals and big diagnostic labs need for gene based diagnosis. Siiquent’s business model is selling two… Continue Reading
One Business, Two Revenue Models? October 8, 2024 The two divisions within the company focus on different markets, and therefore, operate upon different revenue and business models. On one hand, Isolde leads… Continue Reading
BUSINESS: Can One Business Unit Have Two Revenue Models? October 8, 2024 1. Isolde targets hospitals and diagnostic labs, using a “razor-blade” model where the focus is on selling consumables rather than machines. This approach includes… Continue Reading
Can One Business Unit Have Two Revenue Models? October 8, 2024 Which markets do Isolde and Emanuel target respectively? How do their respective business/revenue models align with their markets? Isolded and Siiquent target large hospitals… Continue Reading
Can One Business Unit Have Two Revenue Models? October 8, 2024 First thoughts: a very interesting article and hypothetical! In this case study, Peter, chief of the Diagnostics Division for Scherr Pharmaceuticals is tasks with… Continue Reading
3A BUSINESS: Can One Business Unit Have Two Revenue Models? October 8, 2024 The case of Siiquent and Teomik’s merger under Scherr Pharmaceuticals highlights the challenge of aligning distinct market strategies and revenue models. Siiquent, led by… Continue Reading
